Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases

Safety and Outcomes of Open-Label Deferasirox Iron Chelation Therapy for Mucormycosis

(2009) B. Spellberg et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Risk/Benefit Assessment, Advantages Over Other Drugs and Targeting Methods in the Use of Deferiprone as a Pharmaceutical Antioxidant in Iron Loading and Non Iron Loading Conditions

(2009) George J. Kontoghiorghes et al.   HEMOGLOBIN

Transparency and Access to Full Information for the Fatal or Serious Toxicity Risks, Low Efficacy and High Price of Deferasirox, Could Increase the Prospect of Improved Iron Chelation Therapy Worldwide

(2008) George J. Kontoghiorghes   HEMOGLOBIN

Myocyte Damage and Loss of Myofibers is the Potential Mechanism of Iron Overload Toxicity in Congestive Cardiac Failure in Thalassemia. Complete Reversal of the Cardiomyopathy and Normalization of Iron Load by Deferiprone

(2008) Annita Kolnagou et al.   HEMOGLOBIN

Long Term Comparative Studies in Thalassemia Patients Treated with Deferoxamine or a Deferoxamine/Deferiprone Combination. Identification of Effective Chelation Therapy Protocols

(2008) Annita Kolnagou et al.   HEMOGLOBIN

Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation

(2008) Gian Luca Forni et al.   MOVEMENT DISORDERS